Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, remains a significant global health concern. It is paramount for healthcare professionals to stay abreast of the latest diagnostic and treatment strategies due to the increasing antimicrobial resistance.
Traditionally, blood culture has been the gold standard for diagnosing enteric fever. However, its sensitivity varies based on the disease stage and prior antibiotic use. Newer diagnostic methods like polymerase chain reaction (PCR) and serological tests have shown promise in improving diagnostic accuracy. PCR offers rapid, highly sensitive, and specific detection of Salmonella Typhi and Paratyphi. Serological tests, such as the Typhidot test and Tubex TF test, provide results within hours, aiding in quicker patient management.
Antimicrobial resistance necessitates the continuous updating of treatment regimens. Fluoroquinolones, previously the first-line treatment, are now reserved due to increasing resistance. Current guidelines recommend empiric therapy with third-generation cephalosporins, such as ceftriaxone and cefixime, or azithromycin. For confirmed cases of multidrug-resistant strains, newer agents like meropenem and tigecycline may be used.
Vaccination plays a crucial role in enteric fever prevention. Two vaccines are currently available: an oral live-attenuated Ty21a vaccine and a Vi polysaccharide vaccine. Both vaccines provide substantial protection and are recommended for high-risk populations and travelers to endemic areas.
Advancements in diagnostic methods and evolving treatment regimens have improved the management of enteric fever. Regularly updating knowledge on these advancements is vital for healthcare professionals to provide optimal patient care. Ongoing research and surveillance are crucial to monitor disease trends and resistance patterns, ensuring effective future strategies for enteric fever control.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation